Catalent | CTLT - Le Bénéfice D'Exploitation



Le Bénéfice D'Exploitation Changement Date
Agilent USD 353M 90M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Bruker USD 76.3M 7.6M 2025-12
Centene USD -1.23B 1.03B 2025-12
Charles River Laboratories USD 75.82M 57.98M 2025-12
Cigna USD 2.75B 240M 2025-09
Danaher USD 1.5B 348M 2025-12
Dentsply International USD 538M 26M 2025-12
Elevance Health USD 581M 1.18B 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Hologic USD 237M 16M 2025-12
Humana USD -808M 1.21B 2025-12
Illumina USD 256M 6M 2025-12
Intuitive Surgical USD 865.3M 97.5M 2025-12
IQVIA Holdings USD 2.68B 2.1B 2025-12
J&J USD 5.59B 1.81B 2025-12
Laboratory Of America USD 382M 15.3M 2025-12
Lonza CHF 673M 243M 2025-06
McKesson USD 1.66B 159M 2025-12
Merck EUR 474M 738M 2025-12
Merck USD 6.24B 318M 2025-12
Mettler Toledo International USD 351.93M 57.73M 2025-12
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Quest Diagnostics USD 386M 0 2025-12
Repligen USD 19.97M 7.29M 2025-12
Revvity USD 145.83M 47.49M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Supernus Pharmaceuticals USD 13.82M 74.01M 2025-12
Thermo Fisher Scientific USD 2.3B 226M 2025-12
UnitedHealth USD 3.26B 1.06B 2025-12
Veradigm USD -45.47M 70.47M 2022-12
Waters USD 270.52M 78.4M 2025-12
West Pharmaceutical Services USD 162.5M 5.1M 2025-12